Literature DB >> 498716

Gestational age and indomethacin elimination in the neonate.

M A Evans, R Bhat, D Vidyasagar, M Vadapalli, E Fisher, A Hastreiter.   

Abstract

The disposition of oral indomethacin was studied in 9 premature infants with significant patent ductus arteriosus (sPDA) with birth weights ranging from 800 to 1,960 gm and gestational ages of 28 to 36 wk. Peak plasma concentrations in most of the subjects were not observed until 3 to 4 hr after administration and ranged from 0.027 to 0.31 microgram/ml. Plasma half-life (t1/2) of indomethacin ranged from 11 to 20 hr and correlated with gestational age. Plasma protein binding studies, in samples from the premature infant using radiolabeled indomethacin, showed no difference in binding from values obtained with adult plasma (greater than 98%). Absorption of orally administered indomethacin appears to be incomplete and plasma clearance much longer than in the adult.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498716     DOI: 10.1002/cpt1979266746

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Plasma protein binding of drugs in pregnancy and in neonates.

Authors:  L J Notarianni
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

3.  Patent ductus arteriosus in premature babies.

Authors:  M L Chiswick
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-05

4.  Indomethacin in closure of patent ductus arteriosus.

Authors:  V V Vedanarayanan; I C Verma
Journal:  Indian J Pediatr       Date:  1981 Jul-Aug       Impact factor: 1.967

5.  Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus.

Authors:  P Vert; G Bianchetti; F Marchal; P Monin; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

6.  Clinical Pharmacokinetics of indomethacin.

Authors:  L Helleberg
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

7.  Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study.

Authors:  J M Smyth; P S Collier; M Darwish; J S Millership; H L Halliday; S Petersen; J C McElnay
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  Variability of serum indomethacin concentrations after oral and intravenous administration to preterm infants.

Authors:  R Mrongovius; H Imbeck; L Wille; H Müller; H W Seyberth
Journal:  Eur J Pediatr       Date:  1982-03       Impact factor: 3.183

Review 9.  Pharmacokinetics of common analgesics, anti-inflammatories and antipyretics in children.

Authors:  P D Walson; M E Mortensen
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs.

Authors:  R K Verbeeck; J L Blackburn; G R Loewen
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.